A 58-year-old woman from Greater Manchester has become the first patient worldwide to receive an experimental therapy for advanced cancer as part of a clinical trial conducted by British hospitals. Tracy Tomlinson, diagnosed with ovarian cancer six years ago, is participating in a trial testing a novel treatment known as ZI-MA4-1. The therapy is designed for patients with ovarian cancer, lung cancer, sarcomas, and head and neck cancer—types often associated with limited treatment options at advanced stages.

The trial is being led by the Christie NHS Foundation Trust in Manchester, with additional involvement from the Royal Marsden Hospital in London. The treatment utilizes engineered natural killer cells, which are a component of the immune system capable of destroying abnormal cells. Specifically, T-cell receptors on these cells are modified to recognize and target tumors expressing the MAGE-A4 protein, present in multiple cancer types.

Unlike some personalized treatments, ZI-MA4-1 is manufactured from donor cells in advance, enabling the production of hundreds of doses from a single batch. This approach is intended to reduce manufacturing time and costs compared to therapies tailored individually for each patient.

Tomlinson, a married mother of one from Chadderton, has experienced multiple remissions and relapses since her diagnosis. She was referred to the trial team last year and quickly decided to participate, despite initial apprehensions about being the first to receive the therapy. She has undergone three of a potential four infusions and remains cautiously optimistic. “Every day that I wake up is a positive. You’ve got to have hope,” she said, emphasizing the importance of the treatment for both her and future patients.

Prof Fiona Thistlethwaite, a consultant medical oncologist at the Christie, described the trial as an early-stage but promising advance toward developing new cancer treatments. Her colleague, Dr. Jon Lim, explained that the therapy involves transferring engineered immune cells from donors to patients, enabling these cells to better identify and attack cancer cells. “We’re very excited,” he added.

The trial represents an innovative step in immunotherapy, with potential implications for improving outcomes in cancers that are often difficult to treat with existing methods. Results from this study will be closely monitored to assess the therapy’s safety and effectiveness.